Table 2.
Determinants of high ALT according to AASLD criteria at month 12 after transition from TDF to TAF
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Odds ratio (95% CI) | p* | Odds ratio (95% CI) | p* | |
| Age | 0.97 (0.95–0.99) | 0.021 | 1.01 (0.98 –1.05) | 0.316 |
| BMI (kg/m2) | 1.09 (1.01–1.19) | 0.017 | 1.06 (0.96–1.17) | 0.246 |
| Total cholesterol (mg/dL) | 1.01 (1.00–1.03) | 0.002 | 1.01 (0.99–1.02) | 0.167 |
| Albumin (mg/dL) | 0.56 (0.33–0.95) | 0.034 | 0.54 (0.26–1.34) | 0.105 |
| Total bilirubin (mg/dL) | 1.21 (0.75–1.98) | 0.424 | ||
| INR | 3.63 (0.44–29.87) | 0.230 | ||
| AFP (U/L) | 1.17 (0.94–1.47) | 0.154 | ||
ALT: Alanine transaminase; AASLD: American Association for the Study of Liver Diseases; TDF: Tenofovir Disoproxil Fumarate; TAF: Tenofovir Alafenamide Fumarate; BMI: Body mass index; INR: International normalized ratio; AFP: Alpha fetoprotein; CI: Confidence interval; *: P<0.05.